Number of the records: 1
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
- 1.0472624 - BC 2017 RIV GB eng J - Journal Article
Caisová, V. - Vieru, A. - Kumžáková, Z. - Glaserová, S. - Husniková, H. - Vácová, N. - Krejčová, G. - Paďouková, L. - Jochmanová, I. - Wolf, K. I. - Chmelař, J. - Kopecký, Jan - Ženka, J.
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
Bmc Cancer. Roč. 16, č. 1 (2016), č. článku 940. E-ISSN 1471-2407
Institutional support: RVO:60077344
Keywords : cancer immunotherapy * innate immunity * melanoma * neutrophils * resiquimod * mannan * phagocytosis
Subject RIV: EC - Immunology
Impact factor: 3.288, year: 2016
Background: Using killed microorganisms or their parts to stimulate immunity for cancer treatment dates back to the end of 19th century. Since then, it undergone considerable development. Our novel approach binds ligands to the tumor cell surface, which stimulates tumor phagocytosis. The therapeutic effect is further amplified by simultaneous application of agonists of Toll-like receptors. We searched for ligands that induce both a strong therapeutic effect and are safe for humans.
Permanent Link: http://hdl.handle.net/11104/0269878
Number of the records: 1